HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Stefan Zeuzem Selected Research

danoprevir

1/2015DAUPHINE: a randomized phase II study of danoprevir/ritonavir plus peginterferon alpha-2a/ribavirin in HCV genotypes 1 or 4.
8/2011Antiviral activity of danoprevir (ITMN-191/RG7227) in combination with pegylated interferon α-2a and ribavirin in patients with hepatitis C.
6/2011Treatment of chronic hepatitis C patients with the NS3/4A protease inhibitor danoprevir (ITMN-191/RG7227) leads to robust reductions in viral RNA: a phase 1b multiple ascending dose study.
12/2010Danoprevir, an HCV NS3/4A protease inhibitor, improves insulin sensitivity in patients with genotype 1 chronic hepatitis C.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Stefan Zeuzem Research Topics

Disease

207Infections
03/2024 - 04/2002
170Chronic Hepatitis C
01/2023 - 10/2002
111Fibrosis (Cirrhosis)
03/2024 - 07/2003
78Hepatitis C
12/2022 - 04/2002
50Liver Cirrhosis (Hepatic Cirrhosis)
03/2024 - 01/2008
44Liver Diseases (Liver Disease)
03/2024 - 09/2006
41Hepatocellular Carcinoma (Hepatoma)
04/2023 - 11/2007
38Neoplasms (Cancer)
08/2023 - 02/2002
34Chronic Hepatitis B
01/2023 - 04/2002
17Virus Diseases (Viral Diseases)
01/2023 - 10/2006
14Colorectal Neoplasms (Colorectal Cancer)
04/2024 - 02/2002
14Hepatitis B
01/2023 - 06/2003
13Inflammation (Inflammations)
01/2023 - 10/2006
12Hepatitis D
10/2023 - 01/2011
12End Stage Liver Disease
04/2023 - 09/2012
12Viremia
05/2014 - 04/2002
11Hemorrhage
09/2023 - 01/2013
11Fatigue
01/2022 - 01/2003
11Anemia
03/2016 - 04/2009
10Acute-On-Chronic Liver Failure
01/2024 - 08/2018
10Pathologic Constriction (Stenosis)
10/2023 - 03/2013
10Body Weight (Weight, Body)
05/2014 - 06/2004
9Coinfection
01/2020 - 11/2008
7Neoplasm Metastasis (Metastasis)
04/2024 - 12/2008
7Hepatitis
04/2023 - 11/2004
7Ascites
01/2023 - 09/2012
7Liver Failure
01/2018 - 11/2007
6Inflammatory Bowel Diseases (Inflammatory Bowel Disease)
04/2024 - 11/2004
6Insulin Resistance
08/2020 - 12/2010
6Exanthema (Rash)
03/2016 - 04/2009
5Cholangiocarcinoma
08/2023 - 02/2017
5Chronic Hepatitis D
07/2023 - 03/2010
5Liver Neoplasms (Liver Cancer)
01/2023 - 06/2013

Drug/Important Bio-Agent (IBA)

137Ribavirin (Virazole)FDA LinkGeneric
01/2021 - 12/2002
126Antiviral Agents (Antivirals)IBA
03/2024 - 04/2002
98InterferonsIBA
04/2023 - 10/2002
52RNA (Ribonucleic Acid)IBA
07/2023 - 10/2002
34Interferon-alpha (Interferon Alfa)IBA
01/2023 - 04/2002
33SofosbuvirIBA
03/2024 - 05/2014
29Protease Inhibitors (Protease Inhibitor)IBA
12/2018 - 09/2007
29telaprevirIBA
03/2016 - 10/2006
22Proteins (Proteins, Gene)FDA Link
03/2024 - 08/2004
22Biomarkers (Surrogate Marker)IBA
08/2023 - 01/2010
22Hepatitis B e AntigensIBA
01/2023 - 01/2005
22peginterferon alfa-2a (Pegasys)FDA Link
01/2019 - 10/2002
14Alanine Transaminase (SGPT)IBA
04/2023 - 12/2004
14DNA (Deoxyribonucleic Acid)IBA
01/2023 - 04/2002
12velpatasvirIBA
03/2024 - 12/2015
12Hepatitis B Surface Antigens (HBsAg)FDA Link
01/2023 - 11/2008
12Lamivudine (Epivir)FDA Link
02/2009 - 04/2002
11daclatasvirIBA
01/2018 - 10/2014
11N- (3- amino- 1- (cyclobutylmethyl)- 2,3- dioxopropyl)- 3- (2- ((((1,1- dimethylethyl)amino)carbonyl)amino)- 3,3- dimethyl- 1- oxobutyl)- 6,6- dimethyl- 3- azabicyclo(3.1.0)hexan- 2- carboxamideIBA
01/2016 - 04/2007
10Anti-Bacterial Agents (Antibiotics)IBA
02/2024 - 09/2011
10SphingolipidsIBA
01/2023 - 07/2014
10MicroRNAs (MicroRNA)IBA
10/2020 - 05/2012
10SimeprevirIBA
01/2019 - 06/2012
9BilirubinIBA
11/2021 - 12/2009
9NucleosidesIBA
08/2016 - 08/2007
9faldaprevirIBA
08/2016 - 12/2011
8Tenofovir (Viread)FDA Link
10/2023 - 01/2013
8grazoprevirIBA
01/2022 - 07/2015
8Sorafenib (BAY 43-9006)FDA Link
04/2021 - 07/2008
8ledipasvirIBA
11/2018 - 05/2014
8Vitamin DFDA LinkGeneric
10/2018 - 05/2011
8EnzymesIBA
01/2018 - 11/2004
8sofosbuvir drug combination ledipasvirIBA
01/2018 - 05/2014
8Interferon alpha-2 (Roferon-A)FDA Link
09/2012 - 12/2002
7C-Reactive ProteinIBA
01/2023 - 05/2013
7glecaprevir and pibrentasvirIBA
01/2022 - 10/2017
7elbasvirIBA
01/2022 - 07/2015
7AlbuminsIBA
11/2021 - 12/2007
7Peptide Hydrolases (Proteases)FDA Link
10/2020 - 10/2006
7CholesterolIBA
07/2018 - 04/2006
7hydroxide ionIBA
01/2018 - 06/2009
7deleobuvirIBA
08/2016 - 12/2011
7TelbivudineFDA Link
01/2016 - 12/2007
6CytokinesIBA
01/2021 - 01/2005
6LipidsIBA
08/2020 - 04/2006
6Ritonavir (Norvir)FDA Link
11/2019 - 01/2014
6NucleotidesIBA
01/2017 - 08/2007
6Indicators and Reagents (Reagents)IBA
10/2016 - 11/2004
6Amantadine (Aman)FDA LinkGeneric
01/2013 - 06/2003
5Hemoglobins (Hemoglobin)IBA
01/2023 - 06/2014
5paritaprevirIBA
11/2019 - 01/2014
5Triglycerides (Triacylglycerol)IBA
07/2018 - 07/2003
5ombitasvirIBA
01/2018 - 01/2014
5adefovirIBA
12/2015 - 08/2005
5peginterferon alfa-2b (Pegintron)FDA Link
11/2011 - 06/2004
5adefovir dipivoxil (Hepsera)FDA Link
09/2011 - 12/2003

Therapy/Procedure

214Therapeutics
02/2024 - 04/2002
38Liver Transplantation
11/2023 - 06/2003
12Drug Therapy (Chemotherapy)
08/2023 - 01/2011
10Stents
10/2023 - 01/2014
10Aftercare (After-Treatment)
05/2018 - 08/2007
9Duration of Therapy
01/2017 - 03/2004
6Retreatment
01/2021 - 03/2011
5Lasers (Laser)
04/2024 - 12/2014
5Antibiotic Prophylaxis
04/2023 - 01/2020
5Transplantation
08/2022 - 02/2007
5Drug Tapering
06/2015 - 02/2009